Skip to main content

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Completed · Phase 3 · NCT05216263

Conditions: Chronic Migraine

At a glance

Research payments reported, 2025
$136,952
U.S. investigators named
24
Sites paid
30
Planned or actual enrollment
75

About the trial

Sponsor
AbbVie
Tested
Atogepant (drug)
Dates
Started 2022-03-22; completion 2025-05-02
Results posted
Yes

Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound. The study will assess safety and tolerability of atogepant when added to BOTOX, as well as prospectively evaluate the efficacy of add-on atogepant for migraine prevention. Adverse events and change in disease activity will be monitored. Atogepant is an investigational drug being developed to prevent chronic migraine. Approximately 75 adult participants will be enrolled at approximately 30 sites in the United States. All participants will receive atogepant oral tablet once a day (QD) during the 24-week treatment period, in additio…

From ClinicalTrials.gov, last updated 2026-06-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $136,952 in research payments for this study in 2025 (76 payments).

Products named: Qulipta

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Inova Fairfax Hospital, VA $21,062
  • St Josephs Hospital and Medical Center, AZ $17,385
  • Chattanooga Medical Research LLC $14,508
  • Sarasota Memorial Hospital, FL $11,136
  • University of Miami $9,901
  • Neuro-Pain Medical Center Inc $5,784
  • West Virginia University $4,713
  • Pref Primary Care Physicians Inc $4,375
  • Minneapolis Clinic of Neurology LTD $4,134
  • Beth Israel Deaconess Medical Center, MA $4,002
  • Frontier Clinical Research LLC $3,545
  • Albany Medical College $3,204
  • Integrated Neurology Services PLLC $2,582
  • Kansas Institute of Research $2,494
  • Texas Neurology PA $2,357
  • Dent Neurologic Institute $2,163
  • Achieve Clinical Research LLC $1,999
  • Kansas City Bone and Joint Clinic Overland PArk $1,854
  • Preferred Primary Care Physicians $1,854
  • Neuro PAin Medical Center $1,854
  • Headache Wellness Center $1,854
  • Chattanooga Gastroenterology PC $1,854
  • Neurology Offices of S Fl PLLC $1,854
  • Michigan Headache and Neurological Institute $1,854
  • First Choice Neurology $1,854
  • Lisa G Cook MD Inc $1,545
  • North County Neurology Associates $1,545
  • Michigan Headache And $1,500
  • Dent Neurosciences Research $1,490
  • Thomas Jefferson University $696

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.